Emphysema: Market Study in Brief

The Introduction to the Emphysema Market

The rising geriatric population is a key factor augmenting the global emphysema market as aged people are more prone to falling prey to the disease. The size of the sector is likely to reach USD22.7 billion by 2035 from USD 13.5 billion in 2024, owing to a sluggish but stable pace of advancement, adhering to a CAGR of 4.83% through the forecast period.

Emphysema is a type of lung disorder primarily characterized by shortness of breath. The condition progressively damages the lungs’ air sacs, weakening and cracking the inner walls, which exacerbates breathing difficulties.

Several factors contribute to the development of emphysema, including exposure to chemical fumes, smoking, dust, and air pollutants. Today, various diagnostic tests are available, including lung function tests, chest X-rays, and CT scans, which help in early detection and monitoring of the disease.

The prevalence of respiratory diseases, including emphysema and chronic bronchitis, has been rising worldwide, largely due to environmental conditions and urbanization. Consequently, demand for advanced treatment options, such as smoking cessation therapies, antibiotics, and other medications, has escalated.

Additionally, the availability of modern diagnostic services supports early detection and accelerates market growth. Currently, approximately 210 million people suffer from COPD (Chronic Obstructive Pulmonary Disease) globally.

Increasing urban populations and rising tobacco use are key contributors. The global emphysema market is expected to expand at a CAGR of 6.1% over the forecast period.

Emphysema: Market Segmentation

The global emphysema market is segmented by type, diagnosis, treatment, and end-user.

1. Type: Panlobular and centrilobular emphysema.
2. Diagnosis: Lung function tests, imaging tests (CT scan and X-ray), and others.
3. Treatment:
4. End-User: Hospitals, clinics, surgical centers, and other healthcare facilities.

• Surgery: Lung transplant, bullectomy, and LVRS (Lung Volume Reduction Surgery).
• Therapy: Nutrition therapy, supplemental oxygen, gene therapy, and pulmonary rehabilitation.
• Medications: Bronchodilators, smoking cessation drugs, antibiotics, inhaled steroids, and leukotriene modifiers.

Worldwide Emphysema Market: Regional Analysis

North America is the largest market for emphysema, driven by the widespread use of lung function and imaging tests for diagnosis and the high prevalence of COPD. Market growth is further supported by increasing awareness of risk factors and a strong presence of manufacturers providing advanced emphysema treatments and medications.

Canada is expected to be the fastest-growing market due to advanced diagnostic infrastructure and rising demand for innovative treatment options. South America shows moderate growth, primarily in urban centers with increasing healthcare access.

Meanwhile, Europe and the Asia-Pacific markets are expanding steadily, fueled by rising pollution levels, urbanization, and growing awareness of respiratory health. Globally, the primary driver remains the increasing prevalence of respiratory disorders and the subsequent demand for effective diagnosis and treatment.